| Long-Term Effects of COVID-19 | Lifetime | 83 | AT 1 | 98.97 |
| Metabolism and Genetic Disorders | Lifetime | 242 | AT 3 | 98.95 |
| Cardiomyopathy and Myosin Studies | Lifetime | 173 | AT 1 | 98.85 |
| Mitochondrial Function and Pathology | Lifetime | 364 | AT 2 | 98.76 |
| Takotsubo Cardiomyopathy and Associated Phenomena | Lifetime | 26 | AT 1 | 98.00 |
| Neurological and metabolic disorders | Lifetime | 75 | AT 2 | 98.05 |
| Genetic Neurodegenerative Diseases | Lifetime | 227 | AT 5 | 98.59 |
| Neurogenetic and Muscular Disorders Research | Lifetime | 214 | AT 4 | 97.86 |
| Muscle Physiology and Disorders | Lifetime | 357 | AT 3 | 97.88 |
| Peripheral Neuropathies and Disorders | Lifetime | 275 | AT 7 | 97.81 |
| Glycogen Storage Diseases and Myoclonus | Lifetime | 155 | AT 2 | 97.06 |
| Cardiovascular Effects of Exercise | Lifetime | 566 | AT 4 | 96.97 |
| ATP Synthase and ATPases Research | Lifetime | 430 | AT 5 | 95.82 |
| Hereditary Neurological Disorders | Lifetime | 262 | AT 4 | 95.69 |
| Muscle and Compartmental Disorders | Lifetime | 242 | AT 4 | 95.30 |
| Drug-Induced Ocular Toxicity | Lifetime | 79 | AT 1 | 94.13 |
| Amyotrophic Lateral Sclerosis Research | Lifetime | 443 | AT 2 | 95.51 |
| Infectious Encephalopathies and Encephalitis | Lifetime | 211 | AT 3 | 93.57 |
| Myasthenia Gravis and Thymoma | Lifetime | 457 | AT 1 | 94.88 |
| Neurological diseases and metabolism | Lifetime | 407 | AT 10 | 95.28 |
| Cardiovascular and Diving-Related Complications | Lifetime | 488 | AT 2 | 94.46 |
| Cerebrovascular and genetic disorders | Lifetime | 158 | AT 4 | 93.92 |
| Congenital heart defects research | Lifetime | 954 | AT 3 | 93.95 |
| Neurosurgical Procedures and Complications | Lifetime | 680 | AT 5 | 94.55 |
| Retinal and Optic Conditions | Lifetime | 975 | AT 9 | 95.25 |
| Heparin-Induced Thrombocytopenia and Thrombosis | Lifetime | 373 | AT 5 | 93.35 |
| Inflammatory Myopathies and Dermatomyositis | Lifetime | 560 | AT 3 | 93.28 |
| Metalloenzymes and iron-sulfur proteins | Lifetime | 500 | AT 2 | 93.04 |
| Neurological Complications and Syndromes | Lifetime | 685 | AT 5 | 90.58 |
| Parkinson's Disease and Spinal Disorders | Lifetime | 222 | AT 6 | 90.61 |
| Coenzyme Q10 studies and effects | Lifetime | 277 | AT 6 | 90.39 |
| Nuclear Structure and Function | Lifetime | 859 | AT 14 | 87.46 |
| Alcoholism and Thiamine Deficiency | Lifetime | 839 | AT 4 | 85.26 |
| Moyamoya disease diagnosis and treatment | Lifetime | 953 | AT 7 | 86.21 |
| Intramuscular injections and effects | Lifetime | 552 | AT 2 | 71.82 |
| Long-Term Effects of COVID-19 | 2021-2025 | 165 | AT 2 | 98.02 |
| Peripheral Neuropathies and Disorders | 2021-2025 | 53 | AT 1 | 98.07 |
| Retinal and Optic Conditions | 2021-2025 | 92 | AT 4 | 97.63 |
| Mitochondrial Function and Pathology | 2021-2025 | 197 | AT 5 | 94.48 |
| Heparin-Induced Thrombocytopenia and Thrombosis | 2021-2025 | 42 | AT 1 | 94.27 |
| Pain Mechanisms and Treatments | 2021-2025 | 397 | AT 1 | 89.45 |
| Metabolism and Genetic Disorders | 2021-2025 | 414 | AT 9 | 86.84 |
| Neurological and metabolic disorders | 2021-2025 | 67 | AT 1 | 83.21 |
| Myasthenia Gravis and Thymoma | 2021-2025 | 231 | AT 1 | 87.51 |
| Infectious Encephalopathies and Encephalitis | 2021-2025 | 151 | AT 2 | 75.11 |
| Cerebral Venous Sinus Thrombosis | 2021-2025 | 493 | AT 11 | 77.55 |
| Intramuscular injections and effects | 2021-2025 | 59 | AT 1 | 78.10 |
| Muscle and Compartmental Disorders | 2021-2025 | 207 | AT 2 | 75.67 |
| Glycogen Storage Diseases and Myoclonus | 2021-2025 | 219 | AT 2 | 75.77 |
| Inflammatory Myopathies and Dermatomyositis | 2021-2025 | 574 | AT 2 | 77.33 |
| Hereditary Neurological Disorders | 2021-2025 | 364 | AT 3 | 74.00 |
| Fetal and Pediatric Neurological Disorders | 2021-2025 | 808 | AT 12 | 72.18 |
| ATP Synthase and ATPases Research | 2021-2025 | 529 | AT 9 | 68.27 |
| Poisoning and overdose treatments | 2021-2025 | 515 | AT 1 | 65.98 |
| Amino Acid Enzymes and Metabolism | 2021-2025 | 660 | AT 6 | 62.57 |
| Histiocytic Disorders and Treatments | 2021-2025 | 301 | AT 4 | 62.60 |
| Electroconvulsive Therapy Studies | 2021-2025 | 597 | AT 7 | 63.28 |
| Autoimmune Neurological Disorders and Treatments | 2021-2025 | 916 | AT 18 | 58.10 |
| Neurological Complications and Syndromes | 2021-2025 | 933 | AT 3 | 48.53 |
| Metalloenzymes and iron-sulfur proteins | 2021-2025 | 738 | AT 8 | 46.54 |
| Cerebrovascular and genetic disorders | 2021-2025 | 554 | AT 5 | 44.99 |
| Ion Transport and Channel Regulation | 2021-2025 | 986 | AT 4 | 45.20 |